Skip to main content
SpringerLink
Log in

Use of rHuG-CSF in New Chemotherapy Strategies

  • Chapter
  • First Online:
Twenty Years of G-CSF

Part of the book series: Milestones in Drug Therapy ((MDT))

  • 961 Accesses

Abstract

The discovery of recombinant human granulocyte colony-stimulating factor (rHuG-CSF) and the development of filgrastim as a clinical therapeutic tool allowed physicians to broaden their scope with respect to chemotherapeutic options and goals. From the initial registration trials, filgrastim demonstrated the ability to limit the duration and severity of neutropenia and to reduce the frequency of febrile neutropenia [1, 2]. Filgrastim allowed the maintenance of dose density, enabling the completion of the full doses of chemotherapy on schedule [3]. Furthermore, it enabled the development of more aggressive regimens with increased dose densities and dose intensities.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Crawford J, Ozer H, Stoller R et al (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–70

    Article  PubMed  CAS  Google Scholar 

  2. Trillet-Lenoir V, Green J, Manegold C et al (1993) Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319–24

    Article  PubMed  CAS  Google Scholar 

  3. Renwick W, Pettengall R, Green M (2009) The use of filgrastim for supporting chemotherapy delivery: two decades of experience. Biodrugs 23:175–186

    Article  PubMed  CAS  Google Scholar 

  4. Citron M, Berry D, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventially scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431–1439

    Article  PubMed  CAS  Google Scholar 

  5. Druker B, Tamara S, Buchdunger E et al (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561–566

    Article  PubMed  CAS  Google Scholar 

  6. Treat J, Gonin R, Socinski M et al (2010) A randomised, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced non-small-cell lung cancer. Ann Oncol 21:540–547

    Article  PubMed  CAS  Google Scholar 

  7. Smith T, Khatcheressian J, Lyman G et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidenced-based clinical practice guideline. J Clin Oncol 24:3187–3205

    Article  PubMed  CAS  Google Scholar 

  8. Swain S, Jeong J, Geyer C et al (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362:2053–2065

    Article  PubMed  CAS  Google Scholar 

  9. Drullinsky P, Sugarman S, Fornier M et al (2010) Dose dense cyclophosphamide, methotrexate, flurouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. Clin Breast Cancer 10:440–444

    Article  PubMed  CAS  Google Scholar 

  10. Yardley D, Zubkus J, Inhorn R et al (2010) A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced breast cancer. Clin Breast Cancer 10:367–372

    Article  PubMed  CAS  Google Scholar 

  11. Dragnev K, Hardin S, Pipas J et al (2010) A dose escalation trial of biweekly docetaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors. Chemotherapy 56:135–141

    Article  PubMed  CAS  Google Scholar 

  12. Muller V, Thomssen C, Schmidt M et al (2010) Final results of a phase I/II pilot study of capecitabine with or without vinorelbine after sequential dose-dense epirubicin and paclitaxel in high-risk early breast cancer. BMC Cancer 10:430–437

    Article  PubMed  Google Scholar 

  13. Jones R, Walsh G, Ashley S et al (2009) A randomised pilot phase II study of doxorubicin and cyclophosphamide (AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast cancer. Br J Cancer 100:305–310

    Article  PubMed  CAS  Google Scholar 

  14. Ozer H, Armitage J, Bennett C et al (2000) American Society of Clinical Oncology 2000 update of recommendations for the use if hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 18:3558–3585

    PubMed  CAS  Google Scholar 

  15. Pfreundschuh M, Trumper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104:626–633

    Article  PubMed  CAS  Google Scholar 

  16. Pfreundschuh M, Trumper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634–641

    Article  PubMed  CAS  Google Scholar 

  17. Pfreundschuh M, Schubert J, Ziepert M et al (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 9:105–16

    Article  PubMed  CAS  Google Scholar 

  18. Sieber M, Bredenfeld H, Josting A et al (2003) 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-staged Hodgkin’s lymphoma: results of a pilot study of the German Hodgkin’s Lymphoma Study Group. J Clin Oncol 21:1734–1739

    Article  PubMed  CAS  Google Scholar 

  19. Diehl V, Franklin J, Pfreundschuh M et al (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin’s disease. N Engl J Med 348:2386–2395

    Article  PubMed  CAS  Google Scholar 

  20. Khouri I, Romaguera J, Kantarjian H (1998) Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 16:3803–3809

    PubMed  CAS  Google Scholar 

  21. Moskowitz C, Bertino J, Glassman J (1999) Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma. J Clin Oncol 17:3776–3785

    PubMed  CAS  Google Scholar 

  22. Velasquez W, McLaughlin P, Tucker S et al (1994) ESHAP – an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 12:1169–1176

    PubMed  CAS  Google Scholar 

  23. Pasricha S, Grigg A, Catalano J et al (2008) A multicenter phase 2 study of risk-adjusted salvage chemotherapy incorporating vinorelbine and gemcitabine for relapsed and refractory lymphoma. Cancer 113:3192–3198

    Article  PubMed  CAS  Google Scholar 

  24. Santoro A, Magagnoli M, Spina M et al (2007) Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica 92:35–41

    Article  PubMed  CAS  Google Scholar 

  25. Wilson W, Grossbard M, Pittaluga S et al (2002) Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 99:2685–2693

    Article  PubMed  CAS  Google Scholar 

  26. Dunleavy K, Healey Bird B, Pittaluga S et al (2007) Efficacy and toxicity of dose-adjusted EPOCH-Rituximab in adults with newly diagnosed Burkitt lymphoma. J Clin Oncol 25(18 Suppl):8035

    Google Scholar 

  27. Mead G, Sydes M, Walewski J et al (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13:1264–1274

    Article  PubMed  CAS  Google Scholar 

  28. De Bono J, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154

    Article  PubMed  Google Scholar 

  29. Pivot X, Koralewski P, Hidalgo J et al (2008) A multicenter phase II study of XRP6258 administered as a 1-hr IV infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann Oncol 19:1547–1552

    Article  PubMed  CAS  Google Scholar 

  30. Egerton N (2010) Optimizing ixabepilne treatment schedules in patients with advance or metastatic cancer. Cancer Chemother Pharmacol 66:1005–1012

    Article  PubMed  CAS  Google Scholar 

  31. Thomas E, Gomez H, Li R et al (2007) Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210–5217

    Article  PubMed  CAS  Google Scholar 

  32. Kahl B, Bartlett N, Leonard J et al (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Cancer 116:106–114

    PubMed  CAS  Google Scholar 

  33. Rummel M, Niederle N, Maschmeyer G, et al (2009) Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to CHOP plus Rituximab as first-line treatment of patients with advanced follicular, indolent and mantle cell lymphomas: final results of a randomised phase III study of the StiL (Study Group Indolent Lymphomas, Germany). Blood (ASH Annual Meeting Abstracts) Nov 2009; 114:405

    Google Scholar 

  34. Yaish P, Gazit A, Gilon C et al (1988) Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242:933–935

    Article  PubMed  CAS  Google Scholar 

  35. Kantarjian H, Sawyers C, Hochhaus A et al (2002) Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645–652

    Article  PubMed  CAS  Google Scholar 

  36. Guilhot F, Apperley J, Kim D et al (2007) Dastatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase. Blood 109:4143–4150

    Article  PubMed  CAS  Google Scholar 

  37. Kantarjian H, Giles F, Wunderle L et al (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 354:2542–2551

    Article  PubMed  Google Scholar 

  38. de Labarthe A, Rousselot P, Huguet-Rigal F et al (2007) Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood 109(4):1408–1413

    Article  PubMed  Google Scholar 

  39. First-line Dasatinib plus Conventional Chemotherapy in adults with newly diagnosed Ph-positive ALL (2009). http://clinicaltrials.gov/show/NCT01004497. Last accessed 18th September 2011

  40. Nilotinib and combination chemotherapy in treating patients with newly diagnosed acute lymphoblastic leukemia (2009). http://clinicaltrials.gov/show/NCT00844298. Last accessed 18th September 2011

  41. LoRusso P, Jones S, Koch K et al (2008) Phase I and pharmacokinetic study of lapatinib and docetaxel in patients with advanced cancer. J Clin Oncol 26:3051–3056

    Article  PubMed  CAS  Google Scholar 

  42. Paul B, Trovato J, Thompson J (2008) Lapatinib: a dual tyrosine kinase inhibitor for metastatic breast cancer. Am J Health Syst Pharm 65(18):1703–10

    Article  PubMed  CAS  Google Scholar 

  43. Geyer C, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743

    Article  PubMed  CAS  Google Scholar 

  44. Chu Q, Cianfrocca M, Goldstein L et al (2008) A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin Cancer Res 14:4484–4490

    Article  PubMed  CAS  Google Scholar 

  45. Stornido A, Pegram M, Overmoyer B et al (2008) Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 26:3317–3323

    Article  Google Scholar 

  46. Di Leo A, Gomex H, Aziz Z et al (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26:5544–5552

    Article  PubMed  Google Scholar 

  47. Shepherd F, Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

    Article  PubMed  CAS  Google Scholar 

  48. Herbst R, Prager D, Hermann R et al (2005) TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892–5899

    Article  PubMed  CAS  Google Scholar 

  49. Starling N, Watkins D, Cunningham D et al (2009) Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer. J Clin Oncol 27:5499–5405

    Article  PubMed  CAS  Google Scholar 

  50. Mok T, Wu Y, Thongprasert S et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947–957

    Article  PubMed  CAS  Google Scholar 

  51. Herbst R, Giaccone G, Schiller J et al (2004) Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial. INTACT 2. J Clin Oncol 22:785–794

    Article  PubMed  CAS  Google Scholar 

  52. Demetri G, Oosterom A, Garrett C et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338

    Article  PubMed  CAS  Google Scholar 

  53. Robert F, Sandler A, Schiller J et al (2010) Sunitinib in combination with docetaxel in patients with advance solid tumors: a phase I dose-escalation study. Cancer Chemother Pharmacol 66:669–680

    Article  PubMed  CAS  Google Scholar 

  54. Janeway CA Jr et al (2005) Immunobiology, 6th edn. Garland Science, New York

    Google Scholar 

  55. Nadler L, Stashenko P, Hardy R et al (1980) Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 40:31473154

    Google Scholar 

  56. Ritz J, Schlossman S (1982) Utilization of monoclonal antibodies in the treatment of leukaemia and lymphoma. Blood 59:1–11

    PubMed  CAS  Google Scholar 

  57. Hooks M, Wade C, Millikan W (1991) Murumonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 11:26–37

    PubMed  CAS  Google Scholar 

  58. Maloney D, Grillo-Lopez A, White C et al (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin’s Lymphoma. Blood 90:2188–2195

    PubMed  CAS  Google Scholar 

  59. Hudis C (2007) Trastuzumab – mechanism of action and use in clinical practice. N Engl J Med 357:39–51

    Article  PubMed  CAS  Google Scholar 

  60. Scolnik P (2009) mAbs: a business perspective. MAbs 1:179–184

    Article  PubMed  Google Scholar 

  61. Shaw T, Quan J, Totoritis M (2003) B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis 62(Suppl 2):55–59

    Google Scholar 

  62. Voog E, Morschhauser F, Solal-Celigny P (2003) Neutropenia in patients treated with rituximab. N Engl J Med 348:2691–2694

    Article  PubMed  Google Scholar 

  63. Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164–1174

    Article  PubMed  CAS  Google Scholar 

  64. Coiffier B, Lepetre S, Pedersen L et al (2008) Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1–2 study. Blood 111:1094–1100

    Article  PubMed  CAS  Google Scholar 

  65. Morschhauser F, Dreyling M, Rohatiner A et al (2009) Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin’s lymphoma: a review of the evidence. Oncologist 14(Suppl 2):17–29

    Article  PubMed  CAS  Google Scholar 

  66. Ibritumomab tiuxetan (Zevalin®) Product information. Spectrum Pharmaceuticals

    Google Scholar 

  67. Piccart-Gebhart M, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659–1672

    Article  PubMed  CAS  Google Scholar 

  68. Vogel C, Tan-Chui E (2005) Trastuzumab plus chemotherapy: convincing survival benefit or not? J Clin Oncol 23:4247–4250

    Article  PubMed  CAS  Google Scholar 

  69. Marty M, Cognetti D, Maraninchi D et al (2005) Efficacy and safety of trastuzumab combined with docetaxel in patient with human epidermal growth factor receptor 2-positive metastatic breast cancer given as first-line treatment: results of a randomized phase II trial by the M7701 Study Group. J Clin Oncol 23:4265–4274

    Article  PubMed  CAS  Google Scholar 

  70. Kash J, Barlow W, Albain K, et al (2008) Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. J Clin Oncol 26(suppl) ASCO Meeting Abstracts Aug 18 2008:1033

    Google Scholar 

  71. Sobrero A, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 6:2311–2319

    Article  Google Scholar 

  72. Cutsern E, Kohne C, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417

    Article  Google Scholar 

  73. Miles D, Chan A, Dirix L et al (2010) Phase III Study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28:3239–3947

    Article  PubMed  CAS  Google Scholar 

  74. Cohen M, Gootenberg J, Keegan P et al (2007) FDA drug approval summary: bevacizumab (Avastin®) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12:713–718

    Article  PubMed  CAS  Google Scholar 

  75. Robert N, Dieras V, Glaspy J et al (2011) RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29:1252–1260

    Article  PubMed  CAS  Google Scholar 

  76. Hecht J, Pillai M, Gollard R et al (2010) A randomised, placebo-controlled phase II study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. Clin Colorectal Cancer 2:95–101

    Article  Google Scholar 

  77. PAVES (2009) pegfilgrastim anti-VEGF evaluation study. http://clinicaltrials.gov/ct2/show/NCT00911170 Last accessed 18th September 2011

  78. Anderson K (2005) Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Semin Hematol 42(Suppl 4):S3–8

    Article  PubMed  CAS  Google Scholar 

  79. Palumbo A, Bringhen S, Caravita T et al (2006) Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with myeloma: randomised controlled trial. Lancet 367:825–831

    Article  PubMed  CAS  Google Scholar 

  80. Facon T, Mary J, Hulin C et al (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial. Lancet 370:1209–1218

    Article  PubMed  CAS  Google Scholar 

  81. Weber D, Chen C, Niesvizky R et al (2007) Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 357:2133–2142

    Article  PubMed  CAS  Google Scholar 

  82. Dimopoulos M, Spencer A, Attal M et al (2007) Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 357:2123–2132

    Article  PubMed  CAS  Google Scholar 

  83. Mateos M, Garcia-Sanz R, Colado E et al (2008) Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy? Br J Haematol 140:324–26

    Article  PubMed  CAS  Google Scholar 

  84. Ferrajoli A, Lee B, Schlette E et al (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:5291–97

    Article  PubMed  CAS  Google Scholar 

  85. Wiernik P, Lossos I, Tuscano J et al (2008) Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol 26:4952–4957

    Article  PubMed  Google Scholar 

  86. Witzig T, Vose J, Zinani L et al (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol 22(7):1622–1627

    Article  PubMed  CAS  Google Scholar 

  87. Johnston P, Yuan R, Cavalli F et al (2010) Targeted therapy in lymphoma. J Hematol Oncol 3:45–54

    Article  PubMed  CAS  Google Scholar 

  88. San Miguel J, Blade J, Boccadoro M et al (2006) A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist 11:51–61

    Article  PubMed  CAS  Google Scholar 

  89. Richardson P, Barlogie B, Berensen J et al (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348:2609–2617

    Article  PubMed  CAS  Google Scholar 

  90. San Miguel J, Schlag R, Khuageva N et al (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906–917

    Article  PubMed  CAS  Google Scholar 

  91. Weigert O, Weidmann E, Mueck R et al (2009) A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma – long-term results of a multicenter observation study. Leuk Lymphoma 50:716–22

    Article  PubMed  CAS  Google Scholar 

  92. Andre F, Campone M, O’Regan R et al (2010) Phase I study of Everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol 28:2110–2115

    Article  Google Scholar 

  93. Farmer H, McCabe N, Lord CJ et al (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434:917–921

    Article  PubMed  CAS  Google Scholar 

  94. O’Shaughnessy J, Osborne C, Pippen J et al (2011) Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med 364:205–214

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology and Medical Oncology, Western Hospital, 2nd Floor South, Main Building, Gordon Street, Footscray 3011, Melbourne, VIC, Australia

    William Renwick

Authors
  1. William Renwick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William Renwick .

Editor information

Editors and Affiliations

  1. Amgen Inc., One Amgen Center Drive, Thousand Oaks, 91320, California, USA

    Graham Molineux

  2. MA Foote Associates, Par Five Court 4284, Westlake Village, 91362, California, USA

    MaryAnn Foote

  3. Amgen, Inc., One Amgen Center Dr. 1, Thousand Oaks, 91320, California, USA

    Tara Arvedson

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Basel AG

About this chapter

Cite this chapter

Renwick, W. (2012). Use of rHuG-CSF in New Chemotherapy Strategies. In: Molineux, G., Foote, M., Arvedson, T. (eds) Twenty Years of G-CSF. Milestones in Drug Therapy. Springer, Basel. https://doi.org/10.1007/978-3-0348-0218-5_13

Download citation

Publish with us

Policies and ethics

Search

Navigation